Regulus Therapeutics Inc. (NASDAQ:RGLS) Rating Changes as of May 17, 2018

May 17, 2018 - By Robert Reynolds

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
Big Money Sentiment decreased to 1.16 in Q4 2017. It has change of 0.19, from 2017Q3’s 1.35. The ratio is negative due to Regulus Therapeutics Inc. positioning: 7 sold and 12 reduced. 10 funds amassed positions and 12 increased positions. Investors holded 58.85 million in 2017Q3 but now own 53.17 million shares or 9.64% less.
State Street holds 0% or 47,869 shs in its capital. Brookstone Capital owns 13,200 shs. South Dakota Inv Council accumulated 1.78M shs. Bnp Paribas Arbitrage reported 4 shs or 0% of all its holdings. Geode Capital Management Ltd Limited Liability Company holds 483,951 shs or 0% of its capital. Ascend Cap Ltd Co has invested 0.04% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Susquehanna Intl Gp Llp has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Meeder Asset Mgmt holds 0% or 8,981 shs. Hightower Advsrs Limited Liability Corporation accumulated 21,200 shs. Manufacturers Life Commerce The holds 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 6,057 shs. Bourgeon Cap Mgmt Llc accumulated 0.04% or 70,804 shs. Dowling And Yahnke Ltd Limited Liability Company has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Bvf Incorporated Il invested in 1.75% or 13.97 million shs. Millennium Mngmt Ltd Liability Co invested in 0% or 424,400 shs. Washington-based Washington Trust Bank & Trust has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS).

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

In total 5 analysts cover Regulus (NASDAQ:RGLS). “Buy” rating has 2, “Sell” are 0, while 3 are “Hold”. 40% are bullish. 8 are the (NASDAQ:RGLS)’s analyst reports since December 11, 2017 according to StockzIntelligence Inc. On Tuesday, March 27 the firm earned “Hold” rating by FBR Capital. On Monday, December 11 the rating was maintained by Wedbush with “Buy”. The stock rating was maintained by Wedbush with “Buy” on Thursday, February 8. On Monday, March 12 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Buy” rating by Wedbush. On Thursday, March 8 BMO Capital Markets maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) with “Market Perform” rating. On Wednesday, December 20 Wedbush maintained the shares of RGLS in report with “Buy” rating. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On
20/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
11/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain

RGLS hit $0.71 during the last trading session after $0 change.Since May 17, 2017 it’s 52.76% down thus downtrending. RGLS underperformed the S&P 500 by 64.31%.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is valued at $74.07 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Another two news for Regulus Therapeutics Inc. (NASDAQ:RGLS) were recently brought out by: Globenewswire.com on May 17, 2018 with title “Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global …”. The other Seekingalpha.com‘s article was titled “Regulus Therapeutics’ (RGLS) CEO Joseph Hagan on Q1 2018 Results – Earnings Call Transcript” and brought out on May 11, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.